Propanc Health (PPCH) 0.0188 $PPCH
Biotech Comeback Kids
ACCESSWIRE - Mon Jun 27, 10:25AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 27, 2016 / Propanc Health Group Corporation (PPCH) has just announced significant progress of development activities ahead of the FirstInMan studies for their PRP treatment.
AKAO: 4.00 (+0.21)
Propanc Engages Two Advisory Firms to Identify Strategic Partnering Opportunities
PR Newswire - Tue May 31, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has engaged the services of Maxim Group LLC and Partner International Inc. to initiate potential strategic partnering discussions for the Company's lead product, PRP.
Propanc Completes Successful Roadshow in New York City
PR Newswire - Wed May 11, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company's CEO, Mr. James Nathanielsz, enjoyed a productive week conducting meetings with leading financial institutions and retail brokers in the greater New York area.
FISI: 25.57 (-0.50)
Emerging Growth Apps Company - Making Children Safer and Smarter
ACCESSWIRE - Thu May 05, 7:02AM CDT
MIAMI, FL / ACCESSWIRE / May 5, 2016 / Apps Company, WorldFlix, Inc. (OTC Pink: WRFX) - is an apps company which founded Swantry and Drobbits with children in mind.
Propanc Conducts Successful Scientific Advice Meeting with the MHRA
PR Newswire - Mon May 02, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, announced today a successful meeting was held with the UK Medicines and Healthcare Products Regulatory Agency, confirming the formal preclinical requirements to commence a first-in-man study with the Company's lead product, PRP. As a result, the Company hopes to submit a clinical trial application (CTA) for late stage cancer patients with solid tumors in the UK, early 2017.
Propanc Announces Launch of New Corporate Website
PR Newswire - Fri Apr 29, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the completion of their new website, www.propanc.com, incorporating important new features designed to enhance the experience of the both investors and the broader public keen to understand the Company's technology, its current operations and most importantly, its vision for the future and how it relates to the field of cancer.
Penny Stock Alert: These 4 Small Cap Stocks Are Worth Big Attention Today
ACCESSWIRE - Thu Apr 28, 8:20AM CDT
NEW YORK, NY / ACCESSWIRE / April 28, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. MWOG, PPCH, FDBL and SUNEQ are on high volume watch, particularly MWOG. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 5.47 (+0.10), EBIO: 1.82 (+0.15), PTCT: 7.09 (+0.07), PETX: 6.40 (+0.08), ARRY: 3.62 (+0.06)
Friendable, The Next Hot App - Over 1 Million Downloads & Celebrity Partnerships
ACCESSWIRE - Mon Apr 25, 7:30AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Mobile App Friendable, (OTC Pink: FDBL) to focus on Strategic Celebrity partnerships.
SUNE: 0.34 (unch)
This Biotech Is Up 300 In Two Months
ACCESSWIRE - Wed Apr 20, 9:45AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 20, 2016 / Sean Parker just made an incredible donation, and thus created the "Parker Institute for Cancer Immunotherapy."
CARA: 5.02 (+0.21)
Propanc Files Two More Patents Citing New Compositions of Proenzymes for Cancer Treatment
PR Newswire - Tue Apr 19, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the filing of two more patent applications in the United States regarding new compositions of its lead product, PRP, for treating cancer. The inventions summarize different combinations of the two proenzymes, trypsinogen and chymotrypsinogen, which synergistically enhance their anti-cancer effects, compared to when used in a one to one ratio, or as singular agents.
Time For Another Biotech Rally
ACCESSWIRE - Mon Apr 18, 8:06AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 18, 2016 / Biotech, was down significantly this year, with the iShares Nasdaq Biotech Index (IBB) still down almost 20%. However, it looks to be fighting its way back big time, and there are several opportunities in the biotech market to zero in on.
RPTP: 5.47 (+0.10)
SeeThruEquity Issues Update on Propanc Health Group Corp (OTCQB: PPCH), Highlighting Recent Financing
ACCESSWIRE - Thu Apr 14, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Propanc Health Group Corp (OTCQB: PPCH).
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.13 (+0.01), VVUS: 1.22 (+0.10), PETX: 6.40 (+0.08), GALE: 0.58 (+0.11)
Biotech Companies That Are Progressing Rapidly
ACCESSWIRE - Mon Apr 04, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 4, 2016 / When investing in speculative biotechnology stocks one of the most important factors is cash flow. Does the company have enough financing to get through trials? Because if not, it doesn't matter how fantastic the potential of its treatment or drug may be, if it doesn't have the financial wherewithal to reach that point.
OHRP: 2.74 (unch)
Is Propanc Health Group the Next Breakthrough Biotech Company
ACCESSWIRE - Wed Mar 30, 9:21AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.
EYES: 3.54 (-0.04)
Propanc Announces Institutional Investor Roadshow, April 28th to May 4th
PR Newswire - Tue Mar 29, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company's Chief Executive Officer, James Nathanielsz, is set to visit to New York City for meetings with institutional investors interested to learn more about the Company's future plans for growth. The meetings will be conducted at the headquarters of Consulting for Strategic Growth 1 (CFSG1) Ltd.
Propanc Receives $1.2 Million to Fast Track Animal Safety Studies, GMP Manufacturing and Preclinical Development for Lead Product, PRP
PR Newswire - Mon Mar 21, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company received $1.2 million from an institutional investor in order to fast track its preclinical activities, including GMP (Good Manufacturing Practice) manufacturing and preparation for future patient trials, which the Company hopes to file an application for this year.
Technical Data Influencing the Market -- Analyst Notes on Propanc Health Group, Rocky Mountain High Brands, Schneider Electric and Assa Abloy
ACCESSWIRE - Wed Mar 16, 6:45AM CDT
NEW YORK, NY / ACCESSWIRE / March 16, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Propanc Health Group Corp. (OTC: PPCH), Rocky Mountain High Brands Inc. (OTC: RMHB), Schneider Electric SE (OTC: SBGSY) and Assa Abloy AB (OTC: ASAZY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Biotech Trade Report
ACCESSWIRE - Mon Mar 14, 8:01AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 14, 2016 / Much like this time last year, the biotechnology industry is filled with bulls. If you want to profit on this bullish time for the sector there's a few stocks you should be looking very closely at.
VCEL: 2.26 (+0.01)
Biotech Comeback Kids
ACCESSWIRE - Mon Jun 27, 10:25AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 27, 2016 / Propanc Health Group Corporation (PPCH) has just announced significant progress of development activities ahead of the FirstInMan studies for their PRP treatment.
AKAO: 4.00 (+0.21)
Propanc Engages Two Advisory Firms to Identify Strategic Partnering Opportunities
PR Newswire - Tue May 31, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has engaged the services of Maxim Group LLC and Partner International Inc. to initiate potential strategic partnering discussions for the Company's lead product, PRP. Propanc Completes Successful Roadshow in New York City
PR Newswire - Wed May 11, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company's CEO, Mr. James Nathanielsz, enjoyed a productive week conducting meetings with leading financial institutions and retail brokers in the greater New York area. FISI: 25.57 (-0.50)
Emerging Growth Apps Company - Making Children Safer and Smarter
ACCESSWIRE - Thu May 05, 7:02AM CDT
MIAMI, FL / ACCESSWIRE / May 5, 2016 / Apps Company, WorldFlix, Inc. (OTC Pink: WRFX) - is an apps company which founded Swantry and Drobbits with children in mind.
Propanc Conducts Successful Scientific Advice Meeting with the MHRA
PR Newswire - Mon May 02, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, announced today a successful meeting was held with the UK Medicines and Healthcare Products Regulatory Agency, confirming the formal preclinical requirements to commence a first-in-man study with the Company's lead product, PRP. As a result, the Company hopes to submit a clinical trial application (CTA) for late stage cancer patients with solid tumors in the UK, early 2017. Propanc Announces Launch of New Corporate Website
PR Newswire - Fri Apr 29, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the completion of their new website, www.propanc.com, incorporating important new features designed to enhance the experience of the both investors and the broader public keen to understand the Company's technology, its current operations and most importantly, its vision for the future and how it relates to the field of cancer. Penny Stock Alert: These 4 Small Cap Stocks Are Worth Big Attention Today
ACCESSWIRE - Thu Apr 28, 8:20AM CDT
NEW YORK, NY / ACCESSWIRE / April 28, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. MWOG, PPCH, FDBL and SUNEQ are on high volume watch, particularly MWOG. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 5.47 (+0.10), EBIO: 1.82 (+0.15), PTCT: 7.09 (+0.07), PETX: 6.40 (+0.08), ARRY: 3.62 (+0.06)
Friendable, The Next Hot App - Over 1 Million Downloads & Celebrity Partnerships
ACCESSWIRE - Mon Apr 25, 7:30AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Mobile App Friendable, (OTC Pink: FDBL) to focus on Strategic Celebrity partnerships.
SUNE: 0.34 (unch)
This Biotech Is Up 300 In Two Months
ACCESSWIRE - Wed Apr 20, 9:45AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 20, 2016 / Sean Parker just made an incredible donation, and thus created the "Parker Institute for Cancer Immunotherapy."
CARA: 5.02 (+0.21)
Propanc Files Two More Patents Citing New Compositions of Proenzymes for Cancer Treatment
PR Newswire - Tue Apr 19, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the filing of two more patent applications in the United States regarding new compositions of its lead product, PRP, for treating cancer. The inventions summarize different combinations of the two proenzymes, trypsinogen and chymotrypsinogen, which synergistically enhance their anti-cancer effects, compared to when used in a one to one ratio, or as singular agents. Time For Another Biotech Rally
ACCESSWIRE - Mon Apr 18, 8:06AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 18, 2016 / Biotech, was down significantly this year, with the iShares Nasdaq Biotech Index (IBB) still down almost 20%. However, it looks to be fighting its way back big time, and there are several opportunities in the biotech market to zero in on.
RPTP: 5.47 (+0.10)
SeeThruEquity Issues Update on Propanc Health Group Corp (OTCQB: PPCH), Highlighting Recent Financing
ACCESSWIRE - Thu Apr 14, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Propanc Health Group Corp (OTCQB: PPCH).
Biotech Volatility Both Good And Bad
ACCESSWIRE - Thu Apr 07, 8:31AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
CERU: 2.13 (+0.01), VVUS: 1.22 (+0.10), PETX: 6.40 (+0.08), GALE: 0.58 (+0.11)
Biotech Companies That Are Progressing Rapidly
ACCESSWIRE - Mon Apr 04, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 4, 2016 / When investing in speculative biotechnology stocks one of the most important factors is cash flow. Does the company have enough financing to get through trials? Because if not, it doesn't matter how fantastic the potential of its treatment or drug may be, if it doesn't have the financial wherewithal to reach that point.
OHRP: 2.74 (unch)
Is Propanc Health Group the Next Breakthrough Biotech Company
ACCESSWIRE - Wed Mar 30, 9:21AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.
EYES: 3.54 (-0.04)
Propanc Announces Institutional Investor Roadshow, April 28th to May 4th
PR Newswire - Tue Mar 29, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company's Chief Executive Officer, James Nathanielsz, is set to visit to New York City for meetings with institutional investors interested to learn more about the Company's future plans for growth. The meetings will be conducted at the headquarters of Consulting for Strategic Growth 1 (CFSG1) Ltd. Propanc Receives $1.2 Million to Fast Track Animal Safety Studies, GMP Manufacturing and Preclinical Development for Lead Product, PRP
PR Newswire - Mon Mar 21, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company received $1.2 million from an institutional investor in order to fast track its preclinical activities, including GMP (Good Manufacturing Practice) manufacturing and preparation for future patient trials, which the Company hopes to file an application for this year. Technical Data Influencing the Market -- Analyst Notes on Propanc Health Group, Rocky Mountain High Brands, Schneider Electric and Assa Abloy
ACCESSWIRE - Wed Mar 16, 6:45AM CDT
NEW YORK, NY / ACCESSWIRE / March 16, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Propanc Health Group Corp. (OTC: PPCH), Rocky Mountain High Brands Inc. (OTC: RMHB), Schneider Electric SE (OTC: SBGSY) and Assa Abloy AB (OTC: ASAZY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Biotech Trade Report
ACCESSWIRE - Mon Mar 14, 8:01AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 14, 2016 / Much like this time last year, the biotechnology industry is filled with bulls. If you want to profit on this bullish time for the sector there's a few stocks you should be looking very closely at.
VCEL: 2.26 (+0.01)
